Novartis AG (NVS) Fair Value & Analysis
Healthcare · US · Market cap $278B
Novartis AG
NVS · US
Fair value as of: Jun 24, 2026
From 25 valuation models · updated 8 days ago
Share price +11.4% over the past month.
Price vs Fair Value (12 months)
12‑month range $105.66 – $156.97 · fair‑value band $100.67 – $176.73 · the $153.38 price screens above the $138.70 fair value. As of Jun 24, 2026.
✦ Which stocks are undervalued right now? Check free Discover now →Analysis
Novartis AG (NVS) currently trades at $153.38, while our model-based Fair Value estimate is $138.70 — implying the stock looks roughly 9.6% overvalued today. We read business quality at 82/100 (high quality), in the Healthcare sector. Bear case: priced above our estimate, the market already discounts strong expectations. Bull case: above-average quality can justify a premium — the entry price still matters most (evidence: high).
Over the trailing twelve months, Novartis AG generated revenue of $56.6B at a net margin of 23.9%. Revenue declined 0.7% year over year. It earns a return on equity of 34.9%. Net debt stands at $25.6B. Fundamentals as of Jun 24, 2026
Key figures & financial health
More key figures
Figures from reported company fundamentals (EODHD) · as of Jun 24, 2026. TTM = trailing twelve months.
About the company
Novartis AG researches, develops, manufactures, distributes, markets, and sells pharmaceutical medicines in Switzerland and internationally. The company offers Entresto, an angiotensin receptorneprilysin inhibitor to treat symptomatic chronic heart failure with reduced ejection fraction (HFrEF); Cosentyx to treat plaque psoriasis, pso riatic arthritis, ankylosing spondylitis, and nonradiographic axial spondy loarthritis; Kisqali, a selective oral cyclin dependent inhibitor of kinases 4 and 6 (CDK4/6); Promacta/Revolade to treat immune thrombocytopenia (ITP), thrombocytopenia, and patients with severe aplastic anemia (SAA); Tafinlar+Mekinist, an oral combination therapy to treat patients with certain types of cancers; and Jakavi for the treatment of myelofibrosis, polycythemia vera, and acute or chronic graftversushost disease (GvHD). It also provides Tasigna to treat philadelphia chromosomepositive chronic myeloid leukemia in the chronic and/or accelerated phase; Xolair for the …
Revenue & earnings trend
FY2021 – FY2025 · reported fiscal years
Novartis AG reported revenue of $54.8B in FY2025 versus $44.0B in FY2021, a compound +5.7%/yr. Reported net income was $14.1B in FY2025, compounding −12.5%/yr from FY2021.
Is NVS fairly valued? → Check now
Recent news
- INCY Stock Hits 52-Week High on Regulatory Updates for Opzelura
- Johnson & Johnson (JNJ) Surges 4.0%: Is This an Indication of Further Gains?
- Edison Scientific and Population Health Partners Partner to Build the Next Generation of Biotech Companies
- Will SpaceX Stock Double Anytime Soon? No -- but These 3 Stocks Could
External third-party headlines (Yahoo Finance, Reuters and others) — not an editorial selection, not financial advice.
Similar stocks
6 more Drug Manufacturers - General stocks, each showing price versus our Fair Value estimate (as of Jun 24, 2026).
| Stock | Price | Fair Value | vs Fair Value |
|---|---|---|---|
| Eli Lilly and Company LLY | $1,131 | $447.74 | -60% |
| JNJ JNJ | 4,128 MXN | 159.68 MXN | -96% |
| Johnson & Johnson, JNJB34 | R$78.55 | R$12.18 | -84% |
| AbbVie Inc ABBV | $224.95 | $129.90 | -42% |
| Roche Holding ROGN | 7,050 MXN | 6,743 MXN | -4% |
| Merck & Co MRK | $115.48 | $127.57 | +10% |
Explore undervalued stocks
More undervalued Healthcare stocks →
Frequently asked questions
Is Novartis AG (NVS) undervalued?
What is the fair value of NVS?
What is the quality score of NVS?
What is the revenue of Novartis AG (NVS)?
What is the net profit margin of NVS?
Does Novartis AG pay a dividend?
How we calculate Fair Value
Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data — nothing guessed.
Educational research only · not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.